Traws Pharma Statistics
Total Valuation
Traws Pharma has a market cap or net worth of $15.19 million. The enterprise value is $9.78 million.
Important Dates
The last earnings date was Thursday, November 14, 2024, after market close.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Traws Pharma has 3.03 million shares outstanding. The number of shares has increased by 18.39% in one year.
| Current Share Class | 3.03M |
| Shares Outstanding | 3.03M |
| Shares Change (YoY) | +18.39% |
| Shares Change (QoQ) | -5.03% |
| Owned by Insiders (%) | 2.36% |
| Owned by Institutions (%) | 1.35% |
| Float | 2.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 22.06 |
| Forward PS | 62.04 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 43.27 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.07
| Current Ratio | 1.07 |
| Quick Ratio | 0.90 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -2,255.45% and return on invested capital (ROIC) is -241.25%.
| Return on Equity (ROE) | -2,255.45% |
| Return on Assets (ROA) | -83.72% |
| Return on Capital (ROIC) | -241.25% |
| Revenue Per Employee | $12,556 |
| Profits Per Employee | -$7.82M |
| Employee Count | 18 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.23% in the last 52 weeks. The beta is 1.36, so Traws Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.36 |
| 52-Week Price Change | -73.23% |
| 50-Day Moving Average | 4.96 |
| 200-Day Moving Average | 11.12 |
| Relative Strength Index (RSI) | 50.24 |
| Average Volume (20 Days) | 9,594 |
Short Selling Information
The latest short interest is 7,708, so 0.25% of the outstanding shares have been sold short.
| Short Interest | 7,708 |
| Short Previous Month | 10,350 |
| Short % of Shares Out | 0.25% |
| Short % of Float | 0.34% |
| Short Ratio (days to cover) | 0.36 |
Income Statement
In the last 12 months, Traws Pharma had revenue of $226,000 and -$140.79 million in losses. Loss per share was -$141.78.
| Revenue | 226,000 |
| Gross Profit | 226,000 |
| Operating Income | -24.09M |
| Pretax Income | -18.16M |
| Net Income | -140.79M |
| EBITDA | -24.08M |
| EBIT | -24.09M |
| Loss Per Share | -$141.78 |
Full Income StatementBalance Sheet
| Cash & Cash Equivalents | 5.41M |
| Total Debt | n/a |
| Net Cash | 5.41M |
| Net Cash Per Share | $1.79 |
| Equity (Book Value) | -2.03M |
| Book Value Per Share | -0.67 |
| Working Capital | 575,000 |
Full Balance SheetCash Flow
| Operating Cash Flow | -30.18M |
| Capital Expenditures | n/a |
| Free Cash Flow | -30.18M |
| FCF Per Share | -$9.98 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -10,661.06% |
| Pretax Margin | -62,294.25% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |